ES2111148T3 - Metodo para preparar farmacos administrables por via oral con recubrimiento enterico que contienen compuestos inestables a los acidos. - Google Patents

Metodo para preparar farmacos administrables por via oral con recubrimiento enterico que contienen compuestos inestables a los acidos.

Info

Publication number
ES2111148T3
ES2111148T3 ES93901497T ES93901497T ES2111148T3 ES 2111148 T3 ES2111148 T3 ES 2111148T3 ES 93901497 T ES93901497 T ES 93901497T ES 93901497 T ES93901497 T ES 93901497T ES 2111148 T3 ES2111148 T3 ES 2111148T3
Authority
ES
Spain
Prior art keywords
composite
acids
enteric coating
coating containing
oral route
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93901497T
Other languages
English (en)
Inventor
Dong Sun Min
Kee An Um
Yong Soo Kim
Pyeong Uk Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Discovery Co Ltd
Original Assignee
Sunkyung Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunkyung Industries Ltd filed Critical Sunkyung Industries Ltd
Application granted granted Critical
Publication of ES2111148T3 publication Critical patent/ES2111148T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION ES RELATIVA A UN METODO PARA PREPARAR DROGAS ORALES ENTERICAS CUBIERTAS QUE CONTIENEN COMPUESTO ACIDO INESTABLE, EN PARTICULAR UNA DROGA ORAL ENTERICA CUBIERTA PREPARADA EN LA FORMA DE UNIDADES DE DOSIFICACION ACIDO ESTABLES COMO UNA INCLUSION COMPLEJA FORMADA REACCIONANDO DERIVADO DE BENZOIMIDAZOLO, COMPUESTO ACIDO INESTABLE, CON CICLODEXTRINA EN SOLUCION ALCALINA.
ES93901497T 1991-12-31 1992-12-30 Metodo para preparar farmacos administrables por via oral con recubrimiento enterico que contienen compuestos inestables a los acidos. Expired - Lifetime ES2111148T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR910025847 1991-12-31

Publications (1)

Publication Number Publication Date
ES2111148T3 true ES2111148T3 (es) 1998-03-01

Family

ID=19327322

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93901497T Expired - Lifetime ES2111148T3 (es) 1991-12-31 1992-12-30 Metodo para preparar farmacos administrables por via oral con recubrimiento enterico que contienen compuestos inestables a los acidos.

Country Status (15)

Country Link
US (1) US5399700A (es)
EP (1) EP0619825B1 (es)
JP (1) JP2662518B2 (es)
KR (1) KR960008231B1 (es)
CN (1) CN1033790C (es)
BR (1) BR9207000A (es)
CA (1) CA2127111C (es)
DE (1) DE69222950T2 (es)
EG (1) EG20115A (es)
ES (1) ES2111148T3 (es)
HU (1) HU217135B (es)
MX (1) MX9207676A (es)
RU (1) RU2105773C1 (es)
TW (1) TW224049B (es)
WO (1) WO1993013138A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole
AU745707B2 (en) * 1995-09-21 2002-03-28 Pharma Pass Llc novel composition containing an acid-labile omeprazole and process for its preparation
AU6998796A (en) * 1995-09-21 1997-04-28 Pharma Pass Llc Novel composition containing an acid-labile benzimidazole and process for its preparation
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
NZ337592A (en) * 1997-03-13 2001-01-26 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino/cyclodextrin combinations
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100281521B1 (ko) * 1998-03-31 2001-02-15 김종인 프라바스타틴나트륨이 함유된 약제 조성물
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE69913197T2 (de) * 1998-12-18 2004-09-02 Abbott Laboratories, Abbott Park Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
US20050171057A1 (en) * 2002-01-15 2005-08-04 Altana Pharma Ag Pantoprazole cyclodextrin inclusion complexes
EP1469839A2 (en) * 2002-01-25 2004-10-27 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
KR100473422B1 (ko) * 2003-06-12 2005-03-14 박원봉 렉틴 함유 천연물의 장용성 코팅용 조성물
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
KR20050105565A (ko) * 2004-04-30 2005-11-04 에스케이케미칼주식회사 저장안정성이 우수한 벤즈이미다졸 유도체 함유 포접복합체 및 이의 제조방법
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MX2007008141A (es) * 2005-01-03 2007-12-10 Lupin Ltd Composicion farmaceutica de sustancias labiles en medio acido.
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
ITMI20121264A1 (it) * 2012-07-19 2014-01-20 Recordati Ind Chimica E Farma Ceutica S P A Forma farmaceutica gastro-resistente a rilascio ritardato
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260536C3 (de) * 1972-12-11 1975-07-10 Fa. H. Trommsdorff, 5100 Aachen MolekiileinschluBverbindungen aus einem Silberalkanolammin-Komplex und beta-Cycloheptaamylose, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
US5053240A (en) * 1989-10-24 1991-10-01 Kalamazoo Holdings, Inc. Norbixin adducts with water-soluble or water-dispersible proteins or branched-chain or cyclic polysaccharides

Also Published As

Publication number Publication date
MX9207676A (es) 1993-06-01
CN1076124A (zh) 1993-09-15
TW224049B (es) 1994-05-21
KR960008231B1 (ko) 1996-06-21
EG20115A (en) 1997-07-31
EP0619825B1 (en) 1997-10-29
CA2127111C (en) 1996-05-21
DE69222950T2 (de) 1998-05-28
CA2127111A1 (en) 1993-07-08
HU9401666D0 (en) 1994-09-28
KR930012016A (ko) 1993-07-20
DE69222950D1 (de) 1997-12-04
EP0619825A1 (en) 1994-10-19
HU217135B (hu) 1999-11-29
JP2662518B2 (ja) 1997-10-15
WO1993013138A1 (en) 1993-07-08
RU2105773C1 (ru) 1998-02-27
BR9207000A (pt) 1995-11-28
HUT70494A (en) 1995-10-30
JPH07506088A (ja) 1995-07-06
CN1033790C (zh) 1997-01-15
US5399700A (en) 1995-03-21

Similar Documents

Publication Publication Date Title
ES2111148T3 (es) Metodo para preparar farmacos administrables por via oral con recubrimiento enterico que contienen compuestos inestables a los acidos.
RU94031478A (ru) Способ стабилизации нестабильных в кислой среде соединений
ATE135221T1 (de) Pharmazeutischer kaugummi mit acetylsalicylsäure
NO178564C (no) Framgangsmåte for framstilling av et system for administrering av aktive medikamenter gjennom slimhinner
DE3781730D1 (de) 1-hydroxy-3-(n-methyl-n-propylamino)propan-1,1-diphosphonsaeure verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel.
ES2095059T3 (es) Productos intermedios en un procedimiento para la purificacion de acido clavulanico.
SE402709B (sv) Forfarande for framstellning av ett farmaceutiskt preparat for behandling av hyperkolesterolemi, innehallande p-klorfenoxiisosmorsyra eller vissa estrar eller salter derav
ES2143670T3 (es) Formacion de soluciones acuosas estables de compuestos estannosos.
ES519771A0 (es) Un metodo de producir una preparacion farmaceutica que contiene un derivado de sulfonil urea.
SE7707462L (sv) Forfarande for framstellning av penicillansyraderivat
ES2103486T3 (es) Medicamentos que contienen acidos difosfonicos y sus sales.
ES2073688T3 (es) Rotogranulaciones y revestimiento de enmascaramiento del sabor para la preparacion de tabletas farmaceuticas masticables.
EP0207436A3 (en) New cytidine-diphosphocholine salts, particularly suitable for oral use
DE1913154B2 (de) 2-amino-4-cyclohexylamino-s-triazin-derivate und ihre saeureadditionssalze, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate
AR003434A1 (es) Compuesto de tiludronato, composiciones farmaceuticas que los contienen y proceso para producir dicho compuesto y procedimiento para producir lascomposiciones farmaceuticas.
IT1150852B (it) Mezzi di trasporto, per collegare una macchina di produzione per sigarette con una macchina di confezionamento
SE7509345L (sv) Pyrimidinyltionofosfonsyraestrar till anvendning som insekticider, akaricider och nematocider och sett for deras framstellning.
GR1000264B (el) Μεθοδος παρασκευης παραγωγων ενωσεων ginkgo.
DE3878067D1 (de) 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-heptansaeuren, ihre entsprechenden delta-lactone und salze, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte.
ES2118451T3 (es) Preparado medicamentoso oral que contiene diclofenaco sodico y un acido organico.
AR004682A1 (es) Compuestos acidos fosfinicos sustituidos, metodos para prepararlos, metodos para preparar compuestos intermediarios, composicion farmaceutica y suaplicacion como medicamentos.
HN1999000174A (es) Formulacion medicamentosa acuisa para administracion oral.
FI885638A (fi) Menetelmä lääkeaineina käyttökelpoisten griseoliinihappomonoesterijohdannaisten valmistamiseksi
AT342761B (de) Verfahren zur herstellung von homopyrimidazol-derivate enthaltenden, stabilen pharmazeutischen praparaten zur oralen verabreichung
ES2071843T3 (es) Derivado de acido d-2-(6-metoxi-2-naftil)-propionico opticamente activo y composiciones farmaceuticas que lo contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 619825

Country of ref document: ES